abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
94264: Zika Virus Antibody (IgM) Print View
Zika Virus Ab (IgM) IA     
Pregnant (Y/N)      
Travel in Zika Region?      
Resident of Zika Region?      
Clinical Signs/Symptoms?      
Date of Onset (mm/dd/yy)      
Patient State      

PRIMARY
1 Serum 3 (1) mL   Frozen - 30 Day(s)/Refrigerated - 7 Day(s)  
ALTERNATE
  Serum Separator Tube 3 (1) mL   Refrigerated - 7 Day(s)/Frozen - 30 Day(s)  

Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., a history of clinical signs and symptoms associated with Zika virus infection); CDC Zika virus epidemiological criteria (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiologic criteria for which Zika virus testing may be indicated); and/or the CDC guidelines. Most people with Zika virus infection are asymptomatic. Symptomatic individuals typically experience a mild illness characterized by fever, joint pain, rash, or conjunctivitis. Clinical illness is usually self-limited and lasts a week or less. Not all symptomatic patients report all of these clinical findings, and Zika manifestations overlap significantly with those seen in other viral infections. The incubation period is unclear, but likely to be several days. Symptoms generally resolve on their own within a week. Zika IgM levels over the course of illness are not well characterized. IgM levels are variable, but can usually be detected within the first 2 weeks of symptoms and continuing in some patients for 12 or more weeks. Zika Virus Antibody (IgM) should be tested as a part of multi-test algorithm recommended by the CDC. http://www.cdc.gov/zika/hc-providers/index.html Assay results are for the presumptive identification of IgM antibodies to Zika virus. Pregnant women at risk for Zika virus in the U.S. and in endemic areas are of special concern due to the increased incidence of babies with microcephaly or other congenital defects if mothers are infected during pregnancy. Please refer to the CDC guidelines for the appropriate testing in pregnant women. http://www.cdc.gov/zika/hc-providers/pregnant-woman.html Zika infection shares clinical and epidemiologic features with chikungunya, dengue, and other infections. Molecul

* Collect blood in a serum separator tube (preferred) or a standard
red-top.
* Allow blood to clot at room temperature.
* Blood collection tube should be centrifuged as soon as possible and
serum transferred to a plastic transfer tube in order to avoid
hemolysis.
* Transport refrigerated (cold packs) to local Quest Diagnostics
accessioning laboratory. IMPORTANT: If sample is being shipped
directly to the performing laboratory facility by an overnight
air courier, then transport it frozen on dry ice.
* Specimens must not be left in lock boxes.

Reject Criteria: Plasma; serum received in a frozen serum separator
tube; serum received in an unspun serum separator tube;
serum received in a standard red-top tube (not transferred to plastic
transfer tube); gross lipemia; gross hemolysis
Setup Schedule
Monday-Saturday

Reported (Analytical Time)
4 days

CPT Code
86794

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Transport Temperature: Refrigerated







1996 - 2018 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database